What's Happening?
Spark Biomedical has initiated a Phase II decentralized clinical trial, known as the LUNA Trial, to evaluate a non-pharmaceutical treatment for heavy menstrual bleeding (HMB) using transcutaneous auricular neurostimulation (tAN). This wearable technology
stimulates the nervous system through the ear to potentially reduce menstrual bleeding. The trial, supported by the National Bleeding Disorders Foundation's (NBDF) Pathway to Cures fund, aims to enroll 80 participants across the United States, including adolescents and adults with a history of HMB. The study will focus on women and girls diagnosed with von Willebrand disease, a common inherited bleeding disorder. The trial's primary goal is to assess the reduction in menstrual blood loss, with secondary evaluations on pain, symptom burden, and quality of life. Collaborating institutions include Oregon Health & Science University, the University of Michigan, and Yale University.
Why It's Important?
The LUNA Trial addresses a significant gap in the treatment of heavy menstrual bleeding, particularly for women with inherited bleeding disorders like von Willebrand disease. This condition often leads to missed work or school, affecting nearly half of the women with bleeding disorders. By exploring a non-pharmaceutical approach, the trial could offer a new treatment avenue that avoids the side effects associated with traditional medications. The trial's decentralized nature also reduces barriers to participation, potentially increasing access to innovative treatments. Success in this trial could lead to broader acceptance and use of neurostimulation technologies in managing menstrual health, impacting the quality of life for many women.
What's Next?
As the LUNA Trial progresses, results will determine the effectiveness of transcutaneous auricular neurostimulation in reducing heavy menstrual bleeding. Positive outcomes could lead to further trials and eventual regulatory approval, making this treatment widely available. The trial's findings may also encourage additional research into non-pharmaceutical treatments for other symptoms associated with bleeding disorders. Stakeholders, including healthcare providers and patient advocacy groups, will likely monitor the trial closely, as its success could influence future treatment guidelines and healthcare policies related to menstrual health.
